# US 2008/0188521 A1 · Novel pharmaceutical compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188521 A1
- Document ID: US20080188521A1
- Status: Published application
- Kind: A1
- Application number: 12/012,246
- Filed: 2008-02-01
- Published: 2008-08-07
- Earliest claimed: 2007-02-05
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Erich L. Grimm; Yves Ducharme; Richard Frenette; Richard Friesen; Marc Gagnon; Helene Juteau; Sebastien Laliberte; Bruce MacKay; Yves Gareau
- Web page: https://patentgrep.com/patent/US20080188521A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

## Claims

### Claim 1

A compound of structural Formula I
or a pharmaceutically acceptable salt thereof wherein:
is selected from the group consisting of
wherein the numbers “1” and “2” indicate the points of attachment within structural Formula I;
is selected from a single and a double bond;
A is selected from the group consisting of:
(a) a 5-membered heteroaryl ring containing (i) one or more carbon atoms, (ii) one heteroatom selected from oxygen and sulfur, and (iii) zero, one, two or three nitrogen atoms,
(b) a 5-membered heteroaryl ring containing one or more carbon atoms and from one to four nitrogen atoms,
(c) a 6-membered heteroaryl ring containing carbon atoms and one, two or three nitrogen atoms,
(d) a bicyclic ring system selected from benzothienyl, indolyl, quinolinyl and naphthalenyl,
(e) morpholinyl,
(f) phenyl,
(g) benzyl,
(h) chloro, and
(i) —C(O)C1-3alkyl,
and wherein A is optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of (i) fluorine, (ii) chlorine, (iii) —C1-3 alkyl optionally substituted with one to five fluorines, (iv) —C1-3 alkoxy optionally substituted with one to five fluorines, (v) C3-6 cycloalkyloxy, (vi) —C1-3alkyl-OH, (vii) —COOR8, (viii) —CN, (ix) —NR7R8, and (x) —SO2C1-3alkyl;
W is H or methyl;
X is selected from the group consisting of pyridinyl, -Ph, and —C(R2)(R3)(R4);
Y is selected from —CH2— and —CH2CH2—;
R1 is selected from the group consisting of —H, —C1-6alkyl and —C3-6cycloalkyl;
R1a is selected from the group consisting of: (a) —H, (b) —Cl, (c) —CN, (d) —COOR8, (e) —CONR7R8, (f) —C(S)NR7R8, (g) —S(O)p—C1-3alkyl, (h) —NR7R9, (i) —C(═N—OH)—CH3, (j) —C(═N—OCH3)—CH3, (k) —C(═NH)—OCH3, (l) —C1-6alkyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (m) —C1-3alkyl-O—C1-3alkyl, (n) —C1-3alkoxy optionally substituted with one to five fluorines, (o) —C1-3alkoxy, (p) —C3-6cycloalkyl, (q) phenyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (r) pyridinyl optionally substituted with —C1-3alkyl, particularly methyl, (s) 1-pyrrolidinyl, (t) 4-morpholinyl, and (u) 1-piperazinyl optionally 4N-substituted with —C1-3 alkyl particularly methyl;
p is an integer selected from zero, 1 and 2;
R2 is selected from the group consisting of —H, —OH, —F, —C1-3alkyl, —OC1-3alkyl, —OC(O)—C1-13alkyl, and —OC(O)-phenyl wherein phenyl is optionally substituted with a group selected from —OH and —NO2; and —O-cyclic alkyl ether wherein the cyclic alkyl ether is comprised of one oxygen and 2-5 carbon atoms;
R3 is selected from the group consisting of —H, —C1-6alkyl, —C1-6alkyl substituted with one or more of fluoro, —C1-6alkyl substituted with R6, phenyl, —C2-6alkenyl, —C3-6cycloalkyl, and —C5-7cycloalkenyl;
R4 is selected from the group consisting of —H, —C1-6alkyl, —C1-6alkyl substituted with one or more of fluoro, —C1-6alkyl substituted with R6, phenyl, —C2-6alkenyl, —C3-6cycloalkyl, and —C5-7cycloalkenyl;
or R3 and R4 are joined together with the carbon to which they are attached to form a ring selected from —C3-6cycloalkyl, and a 3-6 membered cyclic alkyl ether comprised of one oxygen and 2-5 carbon atoms; C5-7 cycloalkenyl, provided that there is no double bond at the C-1 position in the ring;
or R2, R3 and R4 are joined together with the carbon to which they are attached to form 1-cyclopentenyl or 1-cyclohexenyl;
R5 is independently selected at each occurrence from the group consisting of —H, —C1-6 alkyl and —C3-6cycloalkyl;
R6 is independently selected at each occurrence from the group consisting of —COOR8, —C(O)H, —CN, —CR5R5OH, —OR5, —S—C1-6alkyl and —S—C3-6 cycloalkyl;
R7 is selected from the group consisting of —H, —C1-6 alkyl, —C3-6 cycloalkyl and —COOR8;
R8 is selected from the group consisting of —H, —C1-6 alkyl and —C3-6 cycloalkyl; and
R9 is independently selected from the group consisting of —H, —C1-6 alkyl, and —C3-6 cycloalkyl, phenyl and benzyl.

### Claim 2 (depends on 1)

The compound of claim 1 having structural formula Ia
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1 having structural formula Ib
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1 having structural formula Ic
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 having structural formula Id
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1 wherein A is selected from (a) a 5-membered aromatic ring containing 3-4 carbon atoms and 1-2 heteroatoms selected from nitrogen, oxygen and sulfur, (b) pyridinyl, and (c) phenyl; wherein A is optionally mono- or di-substituted.

### Claim 7 (depends on 6)

The compound of claim 6 wherein R1 is selected from —H and —C1-6 alkyl, and R1a is selected from the group consisting of —H, cyano, and —CONR7R8.

### Claim 8 (depends on 6)

The compound of claim 6 wherein is a double bond.

### Claim 9 (depends on 8)

The compound of claim 8 wherein Y is selected from —CH2—.

### Claim 10 (depends on 9)

The compound of claim 9 wherein X is —CR2R3R4.

### Claim 11 (depends on 10)

The compound of claim 10 wherein R2 is selected from the group consisting of —H, —OH, —F, —C1-3alkyl, —OCH3, and —OC(O)CH3; R3 is selected from the group consisting of —H, —C1-6alkyl, —C3-6cycloalkyl, phenyl and —C1-6alkyl substituted with one or more of fluoro; and R4 is selected from the group consisting of —H, —C1-6alkyl, —C3-6cycloalkyl, —C1-6alkyl substituted with one or more of fluoro, and —C1-6alkyl substituted with R6.

### Claim 12 (depends on 1)

The compound of claim 1 selected from the group consisting of:
4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;
4-(4-Fluorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(2-Fluoro-phenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(3,5-Difluoro-phenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-phenyl-chromen-2-one;
4-(3-Chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(4-Chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-thiophen-3-yl-chromen-2-one;
4-(3-Ethoxy-phenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-trifluoromethoxy-phenyl)-chromen-2-one;
7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-methoxy-phenyl)-chromen-2-one;
7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-fluoro-phenyl)-chromen-2-one;
7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-methoxy-phenyl)-chromen-2-one;
7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(4-methoxy-phenyl)-chromen-2-one;
7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-phenyl-chromen-2-one;
7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(4-fluoro-phenyl)-chromen-2-one;
4-(4-Fluoro-phenyl)-7-[4-(tetrahydro-pyran-2-yloxymethyl[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(4-Fluoro-phenyl)-7-[4-(1-hydroxy-1-phenyl-ethyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(4-Fluoro-phenyl)-7-[4-(4-hydroxy-tetrahydro-pyran-4-yl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(4-Fluoro-phenyl)-7-[4-(4-methoxy-tetrahydro-pyran-4-yl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(3-fluorophenyl)-7-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-2H-chromen-2-one;
7-[(4-benzyl-1H-1,2,3-triazol-1-yl)methyl]-4-(3-fluorophenyl)-2H-chromen-2-one;
4-(4-Fluorophenyl)-7-[4-(1-oxy-pyridin-2-yl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
7-[4-(Dicyclopropyl-hydroxy-methyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-fluoro-phenyl)-chromen-2-one;
7-[4-(Dicyclopropyl-hydroxy-methyl)-[1,2,3]triazol-1-ylmethyl]-4-(4-fluoro-phenyl)-chromen-2-one;
4-(3-fluorophenyl)-7-{[4-(1-hydroxy-1-(trifluoromethyl)propyl)-5-methyl-1H-1,2,3-triazol-1-yl}methyl]-2H-chromen-2-one;
4-(4-Fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}-amino)methyl]-6-methyl-2H-chromen-2-one;
7-{[4-(1-Cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluorophenyl)-2H-chromen-2-one;
4-(3-Fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)butyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;
4-(3-Methylphenyl)-7-({4-[1-ethyl-1-hydroxypropyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;
7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-pyridin-3-yl-chromen-2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(5-methylisoxazol-3-yl)-2H-chromen-2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(1,3-thiazol-2-yl)-2H-chromen-2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-methoxyisoxazol-5-yl)-2H-chromen-2-one;
7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-isothiazol-5-yl-chromen 2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-oxazol-4-yl)-2H-chromen-2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile;
4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxylic acid;
7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-phenylquinoline-2-carbonitrile;
7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(4-fluorophenyl)quinoline-2-carbonitrile;
7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluoro-phenyl)quinoline-2-carbonitrile;
7-({4-[dicyclopropyl(hydroxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(4-fluorophenyl)quinoline-2-carbonitrile;
7-({4-[dicyclopropyl(hydroxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-fluorophenyl)quinoline-2-carbonitrile;
7-({4-[dicyclopropyl(hydroxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile;
7-{[4-(1-hydroxycyclopentyl)-1H-1,2,3-triazol-1-yl]methyl}-4-phenylquinoline-2-carbonitrile;
7-{[4-(1-methoxycyclopentyl)-1H-1,2,3-triazol-1-yl]methyl}-4-phenylquinoline-2-carbonitrile;
4-chloro-7-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-oxazol-4-yl)quinoline-2-carbonitrile;
7-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-thiazol-4-yl)quinoline-2-carbonitrile;
4-acetyl-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
7-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(1,3-thiazol-4-yl)quinoline-2-carbonitrile;
4-(3,4-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
4-(3,5-dichlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
4-(3,5-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
4-(4-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
4-(3-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
4-(4-fluoro-3-methylphenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-pyridin-3-ylquinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-pyrimidin-5-ylquinoline-2-carbonitrile;
4-[3-(dimethylamino)phenyl]-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(4-methylphenyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-methylphenyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-[3-(methylsulfonyl)phenyl]quinoline-2-carbonitrile;
4-(3,5-dichlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxamide;
4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
4-(3,4-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
4-(3,5-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
4-(4-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
4-(3-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
4-(4-fluoro-3-methylphenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(4-methylphenyl)quinoline-2-carboxamide;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-methylphenyl)quinoline-2-carboxamide;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-[3-(methylsulfonyl)phenyl]quinoline-2-carboxamide;
4-chloro-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
2-(1-{[2-chloro-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;
2-(1-{[2-amino-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;
2-(1-{[2-(benzylamino)-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-pyrrolidin-1-ylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(4-methylpiperazin-1-yl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-morpholin-4-ylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
2-(1-{[2-(dimethylamino)-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-methoxyquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(2,2,2-trifluoroethoxy)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(methylthio)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(methylsulfonyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
2-(1-{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-phenylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-pyridin-3-ylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-methylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1-[4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinolin-2-yl]ethanone;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(1-hydroxy-1-methylethyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(1-hydroxyethyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(1-methoxyethyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;
(1Z)-1-[4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinolin-2-yl]ethanone oxime;
(1E)-1-[4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinolin-2-yl]ethanone O-methyloxime;
7-{2-[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]ethyl}-4-phenylquinoline-2-carbonitrile;
7-(2-{4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}ethyl)-4-phenylquinoline-2-carbonitrile;
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1 selected from the group consisting of:
4-(3-chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
4-(4-chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one
7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-thiophen-3-yl-chromen-2-one;
7-[4-(dicyclopropyl-hydroxy-methyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-fluoro-phenyl)-chromen-2-one;
7-{[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluorophenyl)-2H-chromen-2-one;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one;
4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(4-fluorophenyl)quinoline-2-carbonitrile;
7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluoro-phenyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-pyridin-3-ylquinoline-2-carbonitrile;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1 selected from the group consisting of:
4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;
4-(4-fluorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;
7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-phenyl-chromen-2-one
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile;
4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;
7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxamide;
4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A compound of claim 1 which is (S)-4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A compound of claim 1 which is (S)-4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A compound of claim 1 which is (S)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenyl-2H-chromen-2-one or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A compound of claim 1 which is (S)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A compound of claim 1 which is (S)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxamide or a pharmaceutically acceptable salt thereof.

### Claim at position 20

20-25. (canceled)

### Claim 26 (depends on 1)

A pharmaceutical composition comprised of a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 1)

A method for the treatment of an inflammatory condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

A method for the treatment of atherosclerosis which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 1)

A method for the prophylaxis or reduction of the risk for an atherosclerotic disease event which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 1)

A method for the treatment of asthma which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 1)

A method for the treatment of symptoms associated with allergic rhinitis which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 1)

A method for the treatment of COPD which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
